Physician profile
Mark Stephen Sutton
NPI 1003841248
$5,140.30
in general payments reported to CMS, 2019-2025
23 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $173 · 2021: $287 · 2022: $541 · 2023: $980 · 2024: $1,335 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,697 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.52 |
| Education | $251.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $818.47 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $613.30 | 2019-2025 | Skyrizi, Humira |
| Genzyme Corporation | $519.33 | 2019-2025 | |
| Janssen Biotech, INC. | $483.56 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $393.78 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $333.52 | 2019-2024 | |
| Galderma Laboratories, L.P. | $313.41 | 2024-2025 | Nemluvio |
| Biofrontera INC. | $277.54 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $216.10 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $202.93 | 2020-2025 | Olumiant, Ebglyss, Taltz |
| Incyte Corporation | $176.62 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $133.55 | 2023-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.18 | 2022-2025 | Spevigo |
| Stimlabs LLC | $124.05 | 2025 | Corplex P, Geistlich Derma-Gide |
| Paratek Pharmaceuticals, INC. | $100.70 | 2024-2025 | Nuzyra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $78.62 | 2021-2024 | Dupixent, Libtayo |
| Pfizer INC. | $74.40 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $42.51 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $24.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.67 | 2021 | |
| Novo Nordisk INC | $21.08 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $19.71 | 2021 | |
| Smith+Nephew, INC. | $18.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.